MYOK
Jake B. Bauer - Principal Financial Officer, Sr. VP of Fin. & Corp. Devel. and Assistant Sec. of MyoKardia, Inc.

Person placeholder

Mr. Jake B. Bauer

Principal Financial Officer, Sr. VP of Fin. & Corp. Devel. and Assistant Sec.

Total compensation: $403,837
Age: 39
MyoKardia, Inc. logo

MyoKardia, Inc., a clinical stage biopharmaceutical company, engages in discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is MYK-461, an orally-administered small molecule that is in Phase II clinical trials designed to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy (HCM). The company also develops MYK-491, an orally-administered small molecule that treats genetic dilated cardiomyopathy (DCM) by restoring normal contractility in the diseased DCM heart. In addition, it develops HCM-2, a product candidate to reduce cardiac muscle contractility to normal levels in HCM patients; DCM-2, a product candidate that is intended to increase cardiac muscle contractility to normal levels in genetic DCM patients through a different mechanism than that of MYK-491; and LUS-1, a product candidate, which is intended to counteract a muscle disruption that results in impaired relaxation of the heart. The company has a strategic collaboration with Sanofi S.A. for the research, development, and commercialization of pharmaceutical products to treat, prevent, and diagnose HCM and DCM, as well as additional indications. MyoKardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.

  • MyoKardia, Inc., 333 Allerton Avenue, South San Francisco 94080, United States
  • myokardia.com
  • 650-741-0900
Messenger